Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells (original) (raw)

References

• Assikis VJ, Do KA, Wen S, Wang X, Cho-Vega JH, Brisbay S et al. (2004). Clin Cancer Res 10: 6770–6778.
• Barton BE, Murphy TF, Shu P, Huang HF, Meyenhofer M, Barton A . (2004). Mol Cancer Ther 3: 1183–1191.
• Bettuzzi S, Davalli P, Astancolle S, Carani C, Madeo B, Tampieri A et al. (2000). Cancer Res 60: 28–34.
• Cochet O, Frelin C, Peyron JF, Imbert V . (2006). Cell Signal 18: 449–455.
• Culine S, Droz JP . (2000). Ann Oncol 11: 1523–1530.
• Darnell Jr JE . (1997). Science 277: 1630–1635.
• Debatin KM, Poncet D, Kroemer G . (2002). Oncogene 21: 8786–8803.
• De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI et al. (2004). J Cell Biochem 91: 459–477.
• DeMiguel F, Lee SO, Lou W, Xiao X, Pflug BR, Nelson JB et al. (2002). Prostate 52: 123–129.
• Dhir R, Ni Z, Lou W, DeMiguel F, Grandis JR, Gao AC . (2002). Prostate 51: 241–246.
• El-Hashemite N, Zhang H, Walker V, Hoffmeister KM, Kwiatkowski DJ . (2004). Cancer Res 64: 3436–3443.
• Geney R, Ungureanu M, Ojima I . (2002). Clin Chem Lab Med 40: 918–925.
• Hengartner MO . (2000). Nature 407: 770–776.
• Herr I, Debatin KM . (2001). Blood 98: 2603–2614.
• Ho SM, Leav I, Ghatak S, Merk F, Jagannathan VS, Mallery K . (1998). Am J Pathol 153: 131–139.
• Horvath CM . (2000). Trends Biochem Sci 25: 496–502.
• Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR . (1999). J Biol Chem 274: 6875–6881.
• Johnstone RW, Ruefli AA, Lowe SW . (2002). Cell 108: 153–164.
• July LV, Beraldi E, So A, Fazli L, Evans K, English JC et al. (2004). Mol Cancer Ther 3: 223–232.
• Lacroix H, Ligeza C . (1998). Expert Opin Investig Drugs 7: 273–281.
• Lee SO, Lou W, Johnson CS, Trump DL, Gao AC . (2004). Prostate 60: 178–186.
• Legrand A, Vadrot N, Lardeux B, Bringuier AF, Guillot R, Feldmann G . (2004). Liver Int 24: 149–160.
• Liu K, Caldwell SA, Abrams SI . (2005). Cancer Res 65: 1045–1054.
• Lowe SW, Lin AW . (2000). Carcinogenesis 21: 485–495.
• Kominsky SL, Hobeika AC, Lake FA, Torres BA, Johnson HM . (2000). Cancer Res 60: 3904–3908.
• Makarovskiy AN, Siryaporn E, Hixson DC, Akerley W . (2002). Cell Mol Life Sci 59: 1198–1211.
• Milbank AJ, Dreicer R, Klein EA . (2002). Urology 60: 738–741.
• Miller ML, Ojima I . (2001). Chem Rec 1: 195–211.
• Miyake H, Chi KN, Gleave ME . (2000a). Clin Cancer Res 6: 1655–1663.
• Miyake H, Hara I, Kamidono S, Gleave ME, Eto H . (2003). Oncol Rep 10: 469–473.
• Miyake H, Nelson C, Rennie PS, Gleave ME . (2000b). Cancer Res 60: 170–176.
• Miyake H, Pollak M, Gleave ME . (2000c). Cancer Res 60: 3058–3064.
• Nelson WG, De Marzo AM, Isaacs WB . (2003). N Engl J Med 349: 366–381.
• Nickerson T, Miyake H, Gleave ME, Pollak M . (1999). Cancer Res 59: 3392–3395.
• O'Sullivan J, Whyte L, Drake J, Tenniswood M . (2003). Cell Death Differ 10: 914–927.
• Ouyang XS, Wang X, Lee DT, Tsao SW, Wong YC . (2001). Carcinogenesis 22: 965–973.
• Peto J . (2001). Nature 411: 390–395.
• Petrylak DP . (2005). Urology 65: 3–7.
• Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME et al. (2004). N Engl J Med 351: 1513–1520.
• Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG . (2004). Oncogene 23: 2298–2304.
• Stephanou A, Latchman DS . (2003). Int J Exp Pathol 84: 239–244.
• Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. (2004). N Engl J Med 351: 1502–1512.
• Thomas M, Finnegan CE, Rogers KM, Purcell JW, Trimble A, Johnston PG et al. (2004). Cancer Res 64: 8357–8364.
• Trougakos IP, Gonos ES . (2002). Int J Biochem Cell Biol 34: 1430–1448.
• Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES . (2004). Cancer Res 64: 1834–1842.
• Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S et al. (2004). Nat Med 10: 48–54.
• Zellweger T, Kiyama S, Chi K, Miyake H, Adomat H, Skov K et al. (2003). BJU Int 92: 463–469.
• Zellweger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia BP et al. (2001). J Pharmacol Exp Ther 298: 934–940.

Download references